Compound: Amonafide
SMILES: O=C1N(C(=O)c2cccc3c2c1cc(N)c3)CCN(C)C
InChIKey: UPALIKSFLSVKIS-UHFFFAOYSA-N
Synonyms: Amonafide, 69408-81-7, Nafidimide, Benzisoquinolinedione, NSC-308847, Amonafida, Amonafidum, 3-Amino-N-(2-(dimethylamino)ethyl)naphthalimide, M-FA-142, NSC 308847, AS-1413, 1Q8D39N37L, 1H-Benz(de)isoquinoline-1,3(2H)-dione, 5-amino-2-(2-(dimethylamino)ethyl)-, DTXSID30219562, 5-Amino-2-[2-(dimethylamino)ethyl]-1H-benz[de]isoquinoline-1,3(2H)-dione, MFA-142, 5-amino-2-(2-(dimethylamino)ethyl)-1H-benz(de)isoquinoline-1,3(2H)-dione, MFA 142, RefChem:112239, DTXCID80142053, 5-amino-2-(2-dimethylaminoethyl)benzo(de)isoquinolin-1,3-dione, 1H-benz(de)isoquinoline-1,3(2H)-dione, 5-amino-2-(2-(dimethylamino)ethyl), 11-amino-3-(2-(dimethylamino)ethyl)-3-azatricyclo(7.3.1.0?,13)trideca-1(13),5,7,9,11-pentaene-2,4-dione, Quinamed, 5-Aminomitonafide, 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione, AS-1413(Amonafide), M-FA 142, FA 142, NSC308847, 5-amino-2-(2-(dimethylamino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione, MFCD00866438, MLS000757039, CHEMBL428676, Amonifide, Amonafide (USAN), NAPHTHALIMIDE, 3-AMINO-N-(2-(DIMETHYLAMINO)ETHYL)-, 1217039-92-3, AMONAFIDE [USAN], 5-Amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione, Amonafide [INN], Amonafidum [Latin], Amonafida [Spanish], SMR000528907, Amonafide [USAN:INN], BRN 5344673, Amonofide, UNII-1Q8D39N37L, BIDA, 3-Amino-N-(2-(dimethylamino)ethyl)-1,8-naphthalindicarboximid, AMONAFIDE [MART.], 1H-Benz(de)isoquinoline-1,3(2H)-dione, 5-amino-2-(dimethylamino)ethyl-, NCIMech_000383, AMONAFIDE [WHO-DD], SCHEMBL27226, MLS006010419, MLS006011267, orb1300857, SCHEMBL29352008, CHEBI:94661, CGX-571, HMS3654H19, HMS5079F15, 5-amino-2-(2-dimethylaminoethyl)benzo[de]isoquinoline-1,3-dione, SYB03992, BDBM50033894, CCG-35694, NSC758251, s1367, AKOS015850731, CS-0496, DB05022, NCI-308847, NSC-758251, NCGC00346513-01, AC-22581, AS-56124, HY-10982, NCI60_002643, NS00069846, SW219946-1, D10090, F799339, Q4747531, BRD-K56334280-001-02-8, BRD-K56334280-001-03-6, BRD-K56334280-001-05-1, 1H-Benz[de]isoquinoline-1, 5-amino-2-[2-(dimethylamino)ethyl]-, 5-Amino-2-(2-dimethylamino-ethyl)-benzo[de]isoquinoline-1,3-dione, 1H-Benz[de]isoquinoline-1,3(2H)-dione,5-amino-2-[2-(dimethylamino)ethyl]-, 5-Amino-2-(2-dimethylamino-ethyl)-benzo[de]isoquinoline-1,3-dione (amonafide), 5-Amino-2-(2-dimethylamino-ethyl)-benzo[de]isoquinoline-1,3-dione(Amonafide), 5-Amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione #
Theoretical properties:
molecular_formula: C16H17N3O2
molecular_weight: 283.32 g/mol
exact_mass: 283.132076794 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 21
topological_polar_surface_area: 66.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: H <1 (mg/mL)
Descriptions:
pubchem: 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione is a member of isoquinolines.
chembl: AMONAFIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.
It was being developed as an anti-cancer therapy by Antisoma.
As of 2008, it is in Phase III clinical trials.
e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML). In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.